The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).
 
Roger Li
Stock and Other Ownership Interests - crispr therapeutics; Guardant Health
Consulting or Advisory Role - Arquer Diagnostics; Bristol-Myers Squibb; FerGene; Ferring
Research Funding - CG Oncology
Expert Testimony - CG Oncology
Other Relationship - Predicine
 
Gary D. Steinberg
Stock and Other Ownership Interests - Epivax Therapeutics; Urogen pharma
Honoraria - Aduro Biotech; AstraZeneca; Bristol-Myers Squibb; CG Oncology; enGene; Epivax Oncology; fergene; Ferring; Fidia Farmaceutici S. p. A.; FKD Therapies; Janssen Oncology; MDxHealth; Merck; Pfizer; Photocure; Roche/Genentech; Seagen; Sesen Bio; Urogen pharma
Consulting or Advisory Role - Boston Scientific; CG Oncology; Fidia Farmaceutici S. p. A.; Heat Biologics; MDxHealth; Merck; Natera; photocure; Roche/Genentech; Taris BioMedical
 
Edward M. Uchio
Research Funding - Ambry Genetics; Bayer; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Exact Sciences; GenomeDx; Genomic Health; Janssen Oncology; Merck; Merit Medical Systems; Myovant Sciences; Myovant Sciences; Myriad Genetics; Pfizer; Seagen; Veracyte
(OPTIONAL) Uncompensated Relationships - Bayer; Genomic Health; Janssen Oncology; Merck; Myriad Genetics; Pfizer
 
Donald L. Lamm
No Relationships to Disclose
 
Paras Shah
No Relationships to Disclose
 
Ashish M. Kamat
Honoraria - AstraZeneca (I); Tesaro (I)
Consulting or Advisory Role - Arquer Diagnostics; Asieris Pharmaceuticals; Biological Dynamics; Bristol-Myers Squibb; CG Oncology; Eisai; EnGeneIC; FerGene; Imagin Medical; Janssen; Medac; Merck; Photocure; Protara Therapeutics; Roche; Seagen; Sesen Bio; Theralase; TMC Innovation; Urogen pharma; US Biotest
Research Funding - Adolor; Bristol-Myers Squibb; FerGene; FKD Therapies; Heat Biologics; Janssen/Taris; Merck; NIH; Photocure; Seagen; SWOG; The Leo & Anne Albert Institute for Bladder Cancer Care and Research (AIBCCR)
Patents, Royalties, Other Intellectual Property - Patent: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) joint with UT MD Anderson Cancer Center
Other Relationship - European Urology Oncology; International Bladder Cancer Group (IBCG); International Bladder Cancer Network; Journal of Urology; UroToday
 
Trinity Bivalacqua
No Relationships to Disclose
 
Vignesh T. Packiam
Honoraria - CG Oncology
 
Michael Jon Chisamore
Employment - Merck
Stock and Other Ownership Interests - Merck
 
John McAdory
Employment - CG Oncology
Leadership - CG Oncology
Stock and Other Ownership Interests - CG Oncology; Oncorus
Patents, Royalties, Other Intellectual Property - University of Pittsburgh
 
Paola Grandi
Employment - CG Oncology
Leadership - CG Oncology
Stock and Other Ownership Interests - CG Oncology; Oncorus
Patents, Royalties, Other Intellectual Property - University of Pittsburgh
 
Nataliya Hnat
Stock and Other Ownership Interests - CG Oncology
Consulting or Advisory Role - CG Oncology
 
James Burke
Employment - CG Oncology
Leadership - CG Oncology
Stock and Other Ownership Interests - CG Oncology; OncoMyx Therapeutics
Consulting or Advisory Role - CG Oncology